logo
  Join        Login             Stock Quote

Celgene (CELG): Revlimid Approved In China To Treat Relapsed Or Refractory Multiple Myeloma

 February 11, 2013 08:08 AM
 


(By Balachander) Celgene Corp. (NASDAQ: CELG) said China health regulators have approved its Revlimid drug for treatment of patients with relapsed or refractory multiple myeloma who have received at least one prior therapy.

The Summit, New Jersey-based biopharmaceutical company said the China State Food and Drug Administration (SFDA) granted full approval for Revlimid.

Multiple myeloma is a form of blood cancer that primarily affects older adults and arises from plasma cells in the bone marrow. According to the National Cancer Institute, about 21,700 Americans are diagnosed with multiple myeloma and 10,710 die yearly from the disease.

[Related -Celgene Corporation (NASDAQ:CELG): Why Should You Invest In Celgene In 2014?]

The company expects Revlimid to be available late in the second quarter of 2013.

In addition, Celgene said the U.S. Food and Drug Administration (FDA) accepted its application for Revlimid in patients with relapsed or refractory mantle cell lymphoma (MCL) after prior therapy that included bortezomib. The agency has set a Prescription Drug User Fee Act date of June 5, 2013.

On Friday, the company said the FDA has approved an oral therapy to treat patients with multiple myeloma whose disease progressed after being treated with other cancer drugs.

The stock, which has been trading in the 52-week range of $58.53 to $102.29, rose 1.67 percent in premarket trading on Monday.

iOnTheMarket Premium
Advertisement

Advertisement


Post Comment -- Login is required to post message
Name:  
Alert for new comments:
Your email:
Your Website:
Title:
Comments:
 

rss feed

Latest Stories

article imageChart Says This Retailer's Comeback Isn't Finished

One of the surprises, at least on the surface, of the market's recent swoon was the outperformance of read on...

article imageETF Performance Review: Major Asset Classes | 19 Dec 2014

It’s all about real estate investment trusts (REITs) these days when it comes to bullish performance among read on...

article imageOil and Global Stock Markets Rebounding Sharply

So far so good on our expectation of a 4 to 5% pullback and then a resumption of the bull read on...

article imageGrading the FOMC

Love its members or loathe them, you have to admire the gradual impact the policy-making committee has had read on...

Advertisement
Popular Articles

Advertisement
Daily Sector Scan
Partner Center

Related Articles:

Trying To Beat The Market Is A Fool's Errand
More Articles on: Medical , China



Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.